In the SOLAR-1 trial, treatment with the PI3Kα-specific inhibitor alpelisib in combination with fulvestrant improved outcomes in patients with PIK3CA-mutated ER+ advanced breast cancer [76]. Here, PIK3CA is linked to breast carcinoma.